BI 765049

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

Colorectal CancerColorectal CarcinomaColorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal NeoplasmsGastric CarcinomaGastrointestinal CancerHead and Neck CancerLiver CancerLung Cancer

Phase 1

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

CompletedNCT04752215

Boehringer IngelheimColorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms

Start: 2021-05-18End: 2024-12-17Updated: 2026-02-02

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

RecruitingNCT06091930

Boehringer IngelheimColorectal Cancer, Gastrointestinal Cancer, Head and Neck Cancer +3

Start: 2024-02-16End: 2028-09-10Target: 97Updated: 2026-03-04

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

RecruitingNCT06882746

Boehringer IngelheimColorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma

Start: 2025-03-28End: 2027-05-12Target: 135Updated: 2026-03-17

Related Papers

A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.

Journal of Clinical Oncology2024-06-01

A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6.

Journal of Clinical Oncology2022-06-012 citations

480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6

Regular and Young Investigator Award Abstracts2021-11-012 citations